



DEL Like Never Before

DNA-Encoded Library (DEL) technology involves a novel affinity selection process that integrates chemistry, biology, bioinformatics and computational chemistry to facilitate a rapid drug discovery process, allowing access to more chemical space with lower cost.



In contrast to high throughput screening, DEL requires a very small amount of target protein and minimum assay development. More importantly, it disrupts the concept of “cost-per-well” and allows testing billions of compounds in one tube.

About DELight



DELight provides a self-service platform for clients to explore the pool of DEL molecules without sharing target information.


WuXi AppTec HitS provides a DELight kit containing 58 libraries and 10.8 billion compounds, buffers and a step-by-step online experimental manual. Drug developers perform affinity selection according to the manual and return the sample to WuXi AppTec HitS upon completion. WuXi AppTec HitS is responsible for post-selection processing such as PCR amplification, qPCR determination, purification and DNA analysis.

Clients have the option to purchase the entire package of affinity data if promising hits are discovered. We also offer machine learning (ML) and ML enhanced hit finding options to explore more chemical space for DELight users through our partnership with Schrödinger. However, if no features are identified, the project can be terminated for cost and risk control.



About WuXi AppTec HitS

WuXi AppTec HitS unit provides a one-stop Target-to-Hit services that enable companies in the pharmaceuticals, biotech and academics worldwide to seek premium drug discovery. As an innovation-driven and customer-focused unit, WuXi AppTec HitS helps our partners improve the productivity of advancing hit discovery through high-quality and cost-effective solutions.



With industry-leading capabilities such as protein science, biophysics, DNA-encoded library technology, and structural biology, WuXi AppTec HitS is committed to drive toward the realization of the vision that “Every drug can be made and every disease can be treated”



**One-stop solution,
customizable**

**41+
Billion**

Target exclusivity
For all drug developers
Access to unique scaffolds



Unprecedented data release

**10.8
Billion**

Target confidentiality
For all drug developers
Easy access with reduced risk



**Free access to DEL,
data sharing**

**4.2
Billion**

Target confidentiality
For academic users
Open source

HitS Website: <https://hits.wuxiapptec.com>

Contact Us: DEL_service@wuxiapptec.com

North America: Declan Ryan declan.ryan@wuxiapptec.com

Europe: Dave Madge dave_madge@wuxiapptec.com



Our Vision

“Every drug can be made and every disease can be treated”